Lecture 3 Viral Hepatitis Flashcards
1
Q
- What are the different Hep viruses?
- Which ones have a chronic carrier state?
- Which ones are faecal-oral?
- Which ones are parenteral/sexual?
A
2
Q
- What is the most common form of Hepatits?
- Is it going down in infection? Up?
- What is the biggest concern about those infected with HBV and HCV?
A
- Hep C is the most common with 30k new cases and 4 million are chronic carriers
- Hep B second most common with 1 M in a chronic state
- Hep A is third most common
- The numbers of infected people are going down in general but not for HCV
- The problem with chronic carriers is that they’re unaware they have the disease
3
Q
- What is a significant stat about the widespread of HAV?
- What does it mean to be acutely infected?
A
- About 50% of US population showed antibodies for it pre-vaccine
- High rate of subclinical infections without jaundice
- No chronic carrier state
- Acute infection:
- accesses new host via fecal oral route and then there is a long incubation of 15-50 days
- This is when virus is replicating in intestine and the carrier can spread the infection
- This is prior to clinical symptoms
4
Q
- What is the pre-Icteric phase?
- What is the Icetric phase?
A
- Both these phases are when clinical symptoms start showing
- PreIcteric phase:
- Begins with fever, lack of energy, anorexia and lack of appetite
- Leads to vomiting and diarrhoea
- Icteric phase
- Viremia and liver infection leading to necrosis and inflammation
- Bilirubin excreted in the blood leading to jaundice and melanin in urine to produce dark urine
- usually lasts 1-2 weeks most patients recover on their own.
5
Q
What are the treatments and prevention of HAV?
A
6
Q
- What are the major source of infection?
- how many of them are asymptomatic?
- How long is the immunity developed?
A
- Major source of infection is sexual contact and IV
- 30-50% are asymptomatic
- The antigen appears for 6 months or less followed by the appearance of the Antibody and IgG will last a life time so its life time immunity.
7
Q
- What are the complications of acute hepatitis B infection?
A
- Fulminant?
- 1-3% of cases Co infection with HEP D virus and has high mortality rate 60-90%
- Chronic: lasts longer than 6 months
- Patient are chronic carriers of HBsAg
- Chronic active hepitatis CAH
- Coinfection with Hep D virus and developes hepatic necrosis and hepatocellular carcinoma
- Poor prognosis
8
Q
- How do you prevent Hep B?
- How many vaccines are there?
- What is the recommendation?
- What are the antiviral treatments?
- What is a problem with antivirals?
A
- 3 forms of vaccines:
- Recombivax HB
- Engerix-B
- Twinrix
- Recommended to take 3 doses and 98% protection after complete series
- Antivirals:
- Alpha interferon
- Lamivuidine (Nucleotide analogue)
- Baraculude
9
Q
- How is HCV contracted?
- What are the 5 key points in lecture?
A
How is HCV contracted?
- 40-50% are intravenous drug use
- Transfusions
- Renalhemodyalisis
- tattooing and high risk behavior
Key points:
- The high rate of subclinical cases 60-70%
- Causes of chronic liver disease and cancer
- Chronic carrier state 80%
- The onset of illness is insidious
10
Q
- How do you diagnose HepC?
- What is the traditional antiviral therapy?
- Is there a vaccine?
A
- Diagnosis:
- Abnormal liver function
- Elvated HCV antibodies (By Elisa)
- VIral RNA in PCR serum
- Traditional treatment?
- Alpha interferon
- Pegylated Alpha interferon
- Ribavirin and Pgalpha-Inf combination
- No FDA Approved vaccine
11
Q
- What is the treatment of HCV?
A
- Very effective new antivirals but very expensive
- Two are simepervir
- Its a protease
- Sofosbuvir
- Polymerase used in combination
- Used with PEG-INF and RIbavirin will cure up to 90% of genome 1 HCV
12
Q
What is HDV?
A
13
Q
What are the clinical aspects of HDV?
A
- HDV only present in HBsAg Carriers that may progress to liver cirrhosis or hepatocellular carcinoma (30% mortality)
- Hemophilliacas and IV drug users are at risk
USe Anti HDV antibodies to detect
14
Q
What is HEV?
A
- Wide spread infection cause Acute hepatitis
- 20 M cases/yr 10-30% mortality
- Rare in US
- No antiviral, no vaccine and no chronic infection
15
Q
A